NVSEF — NOVARTIS AG

—
NYSE · Health Care · Pharmaceuticals · CIK 1114448 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-10-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 15,029,000,000 11,421,000,000 1,843,000,000 1,202,000,000 117,149,000,000 8,870,000,000 79,585,000,000
Jun 2026 14,951,000,000 11,241,000,000 4,750,000,000 3,264,000,000 122,033,000,000 7,616,000,000 80,087,000,000
Mar 2026 13,524,000,000 10,065,000,000 4,235,000,000 3,156,000,000 118,532,000,000 6,877,000,000 79,605,000,000
Dec 2025 13,860,000,000 10,249,000,000 3,616,000,000 2,409,000,000 110,949,000,000 11,435,000,000 64,400,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$17,325,000,000
Investing CF
$-18,691,000,000
Financing CF
$778,000,000
CapEx
$-3,324,000,000
Dividends Paid
$-11,553,000,000
Buybacks
$-6,252,000,000
EPS Diluted TTM
$5.24
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$39,239,000,000
Inventory
$6,104,000,000
Receivables
$9,963,000,000
ST Investments
$105,000,000
EBIT TTM
$14,220,000,000
Pretax Income TTM
$12,643,000,000
Interest Exp TTM
$1,577,000,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$56,692,998,144
EBITDA
$23,097,999,360
Free Cash Flow
$11,900,250,112
Enterprise Value
$303,651,979,264
Total Cash
$7,617,999,872
Total Debt
$49,014,001,664
Shares Out
1,900,714,840
Trailing EPS
$6.63
Book Value
$21.86
ROE
30.3%
ROA
10.2%
Div Yield
3.43%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 56,674,000,000 17,644,000,000 13,984,000,000 110,949,000,000 64,400,000,000 46,130,000,000 19,144,000,000
Dec 2024 51,722,000,000 14,544,000,000 11,941,000,000 102,246,000,000 58,120,000,000 44,046,000,000 17,619,000,000
Dec 2023 46,660,000,000 9,769,000,000 14,850,000,000 99,945,000,000 53,195,000,000 46,667,000,000 14,458,000,000
Dec 2022 43,461,000,000 7,946,000,000 6,955,000,000 117,453,000,000 58,030,000,000 59,342,000,000 14,236,000,000

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.26T $1415.55 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABBV AbbVie Inc. $517.59B $292.82 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —

News headlines (Yahoo Finance, 1h cache)

Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term
2026-11-19 06:00 · Yahoo
Aviation Capital Group Delivers First of Four Boeing 737-8 to Norwegian
2026-11-18 22:00 · Yahoo
Former Novartis U.S. Chief Strategy Officer Scott Howell, MD, MBA, Joins GOA Therapeutics as Chief Commercial Officer
2026-11-18 18:30 · Yahoo
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
2026-11-18 14:45 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS
2026-11-18 06:00 · Yahoo
3 Asian Coal Stocks To Watch As LNG Tightens And Utilities Burn More Coal
2026-11-18 04:34 · Yahoo
Drug and Gene Delivery Devices - Global Strategic Business Report 2026: Capitalize on 8.1% CAGR to Secure the $1.2 Billion Market by 2032 as AbbVie, Moderna, Pfizer and Novartis Accelerate
2026-11-17 15:02 · Yahoo
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
2026-11-17 14:50 · Yahoo
FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
2026-11-17 14:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.